Literature DB >> 7174789

Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey.

I J Goldberg, N A Le, J R Paterniti, H N Ginsberg, F T Lindgren, W V Brown.   

Abstract

The role of the enzyme hepatic triglyceride lipase was investigated in a primate model, the cynomolgus monkey. Antisera produced against human postheparin hepatic lipase fully inhibited cynomolgus monkey posttheparin plasma hepatic triglyceride lipase activity. Lipoprotein lipase activity was not inhibited by this antisera. Hepatic triglyceride lipase activity in liver biopsies was decreased by 65-90% after intravenous infusion of this antisera into the cynomolgus monkey. After a 3-h infusion of the antisera, analytic ultracentrifugation revealed an increase in mass of very low density lipoproteins (S(f) 20-400). Very low density lipoprotein triglyceride isolated by isopycnic ultracentrifugation increased by 60-300%. Analytic ultracentrifugation revealed an increase in mass of lipoproteins with flotation greater than S(f) 9 (n = 4). The total mass of intermediate density lipoproteins (S(f) 12-20) approximately doubled during the 3 h of in vivo enzyme inhibition. While more rapidly floating low density lipoproteins (S(f) 9-12) increased, the total mass of low density lipoproteins decreased after infusion of the antibodies. The changes in high density lipoproteins did not differ from those in control experiments. In order to determine whether the increases of plasma concentrations of very low density lipoproteins were due to an increase in the rate of synthesis or a decrease in the rate of clearance of these particles, the metabolism of radiolabeled homologous very low density lipoproteins was studied during intravenous infusion of immunoglobulin G prepared from the antisera against hepatic triglyceride lipase (n = 3) or preimmune goat sera (n = 3). Studies performed in the same animals during saline infusion were used as controls for each immunoglobulin infusion. There was a twofold increase in the apparent half-life of the very low density lipoprotein apolipoprotein-B tracer in animals receiving the antibody, consistent with a decreased catabolism of very low density lipoproteins. Concomitantly, the rise in low density lipoprotein apoprotein-B specific activity was markedly delayed. None of these changes were observed during infusion of preimmune immunoglobulin G.Hepatic triglyceride lipase participates with lipoprotein lipase in the hydrolysis of the lipid in very low density lipoproteins, intermediate density lipoproteins, and the larger low density lipoproteins (S(f) 9-12). Thus, hepatic triglyceride lipase appears to function in a parallel role with lipoprotein lipase in the conversion of very low density and intermediate density lipoproteins to low density lipoproteins (S(f) 0-9).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7174789      PMCID: PMC370335          DOI: 10.1172/jci110717

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Quantitative determination of hepatic and lipoprotein lipase activities from human postheparin plasma.

Authors:  J Boberg; J Augustin; M L Baginsky; P Tejada; W V Brown
Journal:  J Lipid Res       Date:  1977-07       Impact factor: 5.922

2.  The metabolism of chylomicron remnants by isolated perfused rat liver.

Authors:  A D Cooper
Journal:  Biochim Biophys Acta       Date:  1977-09-28

3.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

4.  Comparison of the triglyceride lipase of liver, adipose tissue, and postheparin plasma.

Authors:  J C LaRosa; R I Levy; H G Windmueller; D S Fredrickson
Journal:  J Lipid Res       Date:  1972-05       Impact factor: 5.922

5.  Hypertriglyceridaemia secondary to liver disease.

Authors:  P Müller; R Felin; J Lambrecht; B Agostini; H Wieland; W Rost; D Seidel
Journal:  Eur J Clin Invest       Date:  1974-12-05       Impact factor: 4.686

6.  Determination of lipid phosphorus in the nanomolar range.

Authors:  A Chalvardjian; E Rudnicki
Journal:  Anal Biochem       Date:  1970-07       Impact factor: 3.365

7.  Familial hyperchylomicronemia. Enzymatic and physiologic studies.

Authors:  S Ford; W K Schubert; C J Glueck; R C Bozian
Journal:  Am J Med       Date:  1971-04       Impact factor: 4.965

8.  Metabolism of apoprotein B of plasma very low density lipoproteins in the rat.

Authors:  O Faergeman; T Sata; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

9.  Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia.

Authors:  R M Krauss; R I Levy; D S Fredrickson
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Very low density lipoprotein triglyceride transport in type IV hyperlipoproteinemia and the effects of carbohydrate-rich diets.

Authors:  S H Quarfordt; A Frank; D M Shames; M Berman; D Steinberg
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

View more
  36 in total

1.  Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).

Authors:  C Sandholzer; G Feussner; J Brunzell; G Utermann
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

3.  A missense mutation (Trp86----Arg) in exon 3 of the lipoprotein lipase gene: a cause of familial chylomicronemia.

Authors:  K Ishimura-Oka; F Faustinella; S Kihara; L C Smith; K Oka; L Chan
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

Review 4.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

Review 5.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

6.  The effects of dietary calcium and chlordecone on cholinesterase, triglycerides, low density lipoproteins, and cholesterol in serum of rat.

Authors:  K N Chetty; J Walker; K Brown; G W Ivie
Journal:  Arch Environ Contam Toxicol       Date:  1993-04       Impact factor: 2.804

7.  Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase.

Authors:  A Rubinstein; J C Gibson; J R Paterniti; G Kakis; A Little; H N Ginsberg; W V Brown
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Association of plasma lipoproteins with postheparin lipase activities.

Authors:  I J Goldberg; J J Kandel; C B Blum; H N Ginsberg
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

9.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

10.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.